Cargando…

Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996–2015

Background: Chronic inflammatory diseases are linked to an increased risk of atherothrombotic events, but the risk associated with inflammatory bowel disease (IBD) is controversial. We therefore examined the risk of and risk factors for myocardial infarction (MI) and stroke in IBD patients. Methods:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Golovics, Petra Anna, Verdon, Christine, Wetwittayakhlang, Panu, Filliter, Christopher, Gonczi, Lorant, Hahn, Gustavo Drügg, Wild, Gary E., Afif, Waqqas, Bitton, Alain, Bessissow, Talat, Brassard, Paul, Lakatos, Peter L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837182/ https://www.ncbi.nlm.nih.gov/pubmed/35160136 http://dx.doi.org/10.3390/jcm11030686

Ejemplares similares

Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Hereditary Nonpolyposis Colorectal Cancer in Association with Crohn's Disease and Lynch Syndrome: The Importance of a Strict Endoscopic Surveillance
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

A143 SAFETY OF BIOLOGICAL THERAPIES IN ELDERLY IBD: A SYSTEMATIC REVIEW
por: Golovics, P, et al.
Publicado: (2022)

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
por: Albader, Farah, et al.
Publicado: (2021)

A180 CLINICAL OUTCOMES OF COVID-19 AND IMPACT ON DISEASE COURSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Wetwittayakhlang, P, et al.
Publicado: (2022)

Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes
por: Nene, Sofia, et al.
Publicado: (2020)

Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review
por: Al Khoury, Alex, et al.
Publicado: (2021)

Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?
por: Gonczi, Lorant, et al.
Publicado: (2019)

Time Trends of Environmental and Socioeconomic Risk Factors in Patients with Inflammatory Bowel Disease over 40 Years: A Population-Based Inception Cohort 1977–2020
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease
por: Chao, Che-Yung, et al.
Publicado: (2019)

Do You See What I See? An Assessment of Endoscopic Lesions Recognition and Description by Gastroenterology Trainees and Staff Physicians
por: Hart, Lara, et al.
Publicado: (2020)

A150 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN’S DISEASE
por: Yanofsky, R, et al.
Publicado: (2022)

The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials
por: Wetwittayakhlang, Panu, et al.
Publicado: (2022)

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases
por: Reinglas, Jason, et al.
Publicado: (2018)

Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?
por: Strohl, Matthew, et al.
Publicado: (2018)

The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases
por: Kablawi, Dana, et al.
Publicado: (2023)

Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity—A Retrospective Study
por: Benmassaoud, Amine, et al.
Publicado: (2016)

Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease
por: Alrajhi, Saad, et al.
Publicado: (2020)

Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules
por: Verdon, Christine, et al.
Publicado: (2019)

A191 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kablawi, D, et al.
Publicado: (2023)

Transition care in inflammatory bowel disease: A needs assessment survey of Quebec gastroenterologists and allied nurses
por: Strohl, Matthew, et al.
Publicado: (2017)

Therapeutic preferences and outcomes in newly diagnosed patients with Crohn’s diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database
por: Kurti, Zsuzsanna, et al.
Publicado: (2018)

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
por: Gonczi, Lorant, et al.
Publicado: (2017)

Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
por: Heron, Valerie, et al.
Publicado: (2022)

Adenocarcinoma Within Carpet-Like Pseudopolyposis
por: Xiao, Yasi, et al.
Publicado: (2020)

Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohn’s Disease
por: Verdon, Christine, et al.
Publicado: (2020)

Macrosomia, Perinatal and Infant Mortality in Cree Communities in Quebec, 1996-2010
por: Xiao, Lin, et al.
Publicado: (2016)

A34 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kablawi, D, et al.
Publicado: (2023)

Primary Hepatic Angiosarcoma: A Rare Liver Malignancy − Varying Manifestations but Grave Prognosis
por: Rujeerapaiboon, Natthapat, et al.
Publicado: (2020)

Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape
por: LeBlanc, Jean-Frédéric, et al.
Publicado: (2019)

Objective Disease Monitoring Strategies from a Tertiary Inflammatory Bowel Disease Center in Hungary
por: Lontai, Livia, et al.
Publicado: (2023)

Endoscopic management of Crohn’s strictures
por: Bessissow, Talat, et al.
Publicado: (2018)

Esophageal Squamous Cell Carcinoma With Colonic Metastases
por: Wiseman, Daniel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9ato1qraa9sl48p5ktn1ubkshp